Vion Pharmaceuticals is planning to conduct a pivotal phase II trial of its anticancer agent Cloretazine in elderly patients with poor-risk acute myelogenous leukemia. Elderly poor-risk acute myelogenous leukemia (AML) is the disorder in patients over sixty years of age that have certain risk factors affecting the outcome of treatment.
